Submission Support: Cybersecurity Expertise Through Every Stage of FDA Review
The Challenge: Submission Readiness Starts Earlier Than You Think
For medical device manufacturers, the difficult part of a cybersecurity submission is rarely assembling one more document. The harder problem is making sure the entire body of evidence tells the same story. Architecture, threat modeling, security risk management, penetration testing, vulnerability management, labeling, and postmarket plans all have to align with the device that was actually designed and with the claims made in the submission.
That alignment becomes harder as a program matures. Early in development, teams may know they have gaps but not know which ones will matter most later. Near submission, most of the documentation may be complete, yet small inconsistencies can create significant review questions. After an FDA request for additional information, the challenge changes again: the team must understand what the reviewer is really asking, determine whether the issue is isolated or systemic, and build a response that closes the question without creating new ones.
Cybersecurity submission readiness cannot be left until the end of product development.
FDA expects manufacturers to provide documentation that reflects cybersecurity decisions and activities carried out throughout the product lifecycle. If gaps are discovered only when the submission is being assembled, they may point to work that needs to be revisited in the device design, risk management, testing, vulnerability management, or supporting documentation. Finding those issues earlier gives teams more time to address them before they become submission delays.
The Solution: Support Matched to Where You Are
MedSec's Submission Support offering is structured around three common moments in the regulatory journey. Instead of forcing every manufacturer into the same engagement, the work starts with the current stage of the submission and the decision the team needs to make next.
Option 1: Early Review
For teams that have started cybersecurity documentation but do not yet have a complete package, an early review helps identify gaps, priorities, and direction before those gaps become expensive to unwind. MedSec can review the work already completed, look for missing or weak evidence, and provide feedback on areas that need improvement. The value is timing: findings can still influence the documentation, testing, and risk-management work that follows.
Option 2: FDA Mock Submission
For teams with most or all submission documentation prepared, the FDA Mock Submission provides a pre-submission challenge of the package. MedSec reviews the material with the kinds of questions, connections, and evidence expectations that can arise during cybersecurity review, then identifies areas that could prompt additional information requests. This gives the manufacturer an opportunity to strengthen the package before it enters the formal review process.
Option 3: Deficiency Support
When FDA has already issued requests for additional information, MedSec helps the manufacturer interpret the cybersecurity questions, assess the supporting documentation, and develop a focused response strategy. Depending on the issue, that can include reviewing existing evidence, identifying additional work needed, refining technical rationale, and helping the team present the response clearly and consistently.
Success: Fewer Surprises, Better Decisions, Stronger Responses
A successful submission-support engagement does not depend on predicting every question a reviewer could ask. It improves the manufacturer's position by finding avoidable weaknesses sooner and by making the cybersecurity evidence easier to follow. That can mean discovering a disconnect between the threat model and security risk assessment during an early review, strengthening the rationale around testing before submission, or recognizing that an FDA question points to a broader documentation issue that should be addressed consistently across the package.
The practical win is a team that knows where the submission is strong, where it needs work, and what evidence supports its cybersecurity story. When questions do arise, the manufacturer is better prepared to respond from an organized technical and regulatory foundation rather than starting from scratch under review timelines.
The MedSec Difference: Regulatory Perspective Meets Medical Device Cybersecurity Depth
Submission support is most useful when the reviewer understands both sides of the package: the technical cybersecurity work and how that work is evaluated in a medical device regulatory context. MedSec specializes in medical device and healthcare cybersecurity, with services spanning threat modeling, penetration testing, architecture and design review, security compliance, and regulatory submission support. That breadth matters because a submission question about one document often traces back to work performed somewhere else in the product lifecycle.
MedSec's FDA Mock Submission is developed and led by a former FDA cybersecurity policy lead. During his FDA tenure, his work included premarket and postmarket cybersecurity policy development and implementation across clinical review offices, support for cybersecurity premarket reviews across CDRH, and implementation of requirements under section 524B. That experience adds a perspective that is difficult to reproduce through guidance interpretation alone.
The result is support grounded in how medical device cybersecurity is built, documented, tested, and reviewed. Whether a manufacturer is months from submission, preparing to file, or responding to FDA feedback, MedSec can enter at the point where the team needs help and focus the work on the next regulatory objective.
A Better Time to Find the Problem
The best time to discover a cybersecurity submission gap is while there is still room to address it deliberately. The next best time is before the response clock makes every decision harder. MedSec Submission Support gives manufacturers a way to bring experienced cybersecurity and regulatory review into the process at either point, with the goal of making the package clearer, more defensible, and better prepared for FDA scrutiny.
Comments